The yin yang of bacterial polysaccharides: Lessons learned from B. fragilis PSA

Immunological Reviews

Volumn 245, Issue 1, 2012, Pages 13-26

  Surana, Neeraj K ^a,b,c   Kasper, Dennis L ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Bacteroides fragilis; Host microbe interactions; Immune system ontogeny; Polysaccharide a (PSA); Zwitterionic polysaccharides (ZPSs)

Indexed keywords

BACTERIAL POLYSACCHARIDE; INTERLEUKIN 10; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; ZWITTERIONIC POLYSACCHARIDE;

BACTERIAL GROWTH; BACTEROIDES FRAGILIS; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; HUMAN; IMMUNOMODULATION; INTESTINE FLORA; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; REVIEW; SYMBIOSIS; TH17 CELL;

BACTEROIDES FRAGILIS; BACTEROIDES INFECTIONS; HOMEOSTASIS; HOST-PARASITE INTERACTIONS; HUMANS; IMMUNOMODULATION; INFLAMMATION; INTESTINES; POLYSACCHARIDES, BACTERIAL; YIN-YANG;

EID: 83655193522     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2011.01075.x     Document Type: Review

References (163)

1. Koch R. Untersuchungen über Bakterien: V. Die Ätiologie der Milzbrand-Krankheit, begründet auf die Entwicklungsgeschicte des Bacillus anthracis. Cohns Beitrage zur Biologie der Pflanzen 1876;2:277-310.
2. Kendall AI. Some observations on the study of the intestinal bacteria. J Biol Chem 1909;6:499-507.
3. Isenberg HD. Pathogenicity and virulence: another view. Clin Microbiol Rev 1988;1:40-53.
4. Dobzhansky T. Genetics of the Evolutionary Process. New York: Columbia University Press, 1971.
5. Luckey TD. Introduction to intestinal microecology. Am J Clin Nutr 1972;25:1292-1294.
6. Pasteur L. Observations relatives a la Note Precedente d. M. Duclaux. C R Acad Sci III 1885;100:68.
7. Cohendy M. Experiences sur la vie sans microbes. Ann Inst Pasteur 1912;26:106-137.
8. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005;307:1915-1920.
9. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001;292:1115-1118.
10. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001;291:881-884.
11. Smith K, McCoy KD, Macpherson AJ. Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. Semin Immunol 2007;19:59-69.
12. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009;9:313-323.
13. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577-594.
14. Tlaskalova-Hogenova H, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004;93:97-108.
15. Wen L, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008;455:1109-1113 Epub 2008 Sep 1121.
16. Wu HJ, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010;32:815-827.
17. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-920.
18. Ege MJ, et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med 2011;364:701-709.
19. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989;299:1259-1260.
20. Ehlers S, Kaufmann SH. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: lifestyle changes affecting the host-environment interface. Clin Exp Immunol 2010;160:10-14.
21. Ley RE, et al. Evolution of mammals and their gut microbes. Science 2008;320:1647-1651.
22. Moore WE, Holdeman LV. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol 1974;27:961-979.
23. Gorbach SL, Bartlett JG. Anaerobic infections (second of three parts). N Engl J Med 1974;290:1237-1245.
24. Polk BF, Kasper DL. Bacteroides fragilis subspecies in clinical isolates. Ann Intern Med 1977;86:569-571.
25. Onderdonk AB, Kasper DL, Cisneros RL, Bartlett JG. The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis 1977;136:82-89.
26. Bartlett JG, Onderdonk AB, Louie T, Kasper DL, Gorbach SL. A review. Lessons from an animal model of intra-abdominal sepsis. Arch Surg 1978;113:853-857.
27. Krinos CM, Coyne MJ, Weinacht KG, Tzianabos AO, Kasper DL, Comstock LE. Extensive surface diversity of a commensal microorganism by multiple DNA inversions. Nature 2001;414:555-558.
28. Tzianabos AO, Onderdonk AB, Rosner B, Cisneros RL, Kasper DL. Structural features of polysaccharides that induce intra-abdominal abscesses. Science 1993;262:416-419.
29. Liu CH, Lee SM, Vanlare JM, Kasper DL, Mazmanian SK. Regulation of surface architecture by symbiotic bacteria mediates host colonization. Proc Natl Acad Sci USA 2008;105:3951-3956.
30. Xu J, et al. Evolution of symbiotic bacteria in the distal human intestine. PLoS Biol 2007;5:e156.
31. Kasper DL, Onderdonk AB, Crabb J, Bartlett JG. Protective efficacy of immunization with capsular antigen against experimental infection with Bacteroides fragilis. J Infect Dis 1979;140:724-731.
32. Onderdonk AB, Markham RB, Zaleznik DF, Cisneros RL, Kasper DL. Evidence for T cell-dependent immunity to Bacteroides fragilis in an intraabdominal abscess model. J Clin Invest 1982;69:9-16.
33. Shapiro ME, Onderdonk AB, Kasper DL, Finberg RW. Cellular immunity to Bacteroides fragilis capsular polysaccharide. J Exp Med 1982;155:1188-1197.
34. Chung DR, et al. CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol 2003;170:1958-1963.
35. Ruiz-Perez B, et al. Modulation of surgical fibrosis by microbial zwitterionic polysaccharides. Proc Natl Acad Sci USA 2005;102:16753-16758.
36. Zaleznik DF, Finberg RW, Shapiro ME, Onderdonk AB, Kasper DL. A soluble suppressor T cell factor protects against experimental intraabdominal abscesses. J Clin Invest 1985;75:1023-1027.
37. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA 2010;107:12204-12209.
38. Baumann H, Tzianabos AO, Brisson JR, Kasper DL, Jennings HJ. Structural elucidation of two capsular polysaccharides from one strain of Bacteroides fragilis using high-resolution NMR spectroscopy. Biochemistry (Mosc) 1992;31:4081-4089.
39. Kasper DL, Weintraub A, Lindberg AA, Lonngren J. Capsular polysaccharides and lipopolysaccharides from two Bacteroides fragilis reference strains: chemical and immunochemical characterization. J Bacteriol 1983;153:991-997.
40. Tzianabos AO, Pantosti A, Baumann H, Brisson JR, Jennings HJ, Kasper DL. The capsular polysaccharide of Bacteroides fragilis comprises two ionically linked polysaccharides. J Biol Chem 1992;267:18230-18235.
41. Tzianabos AO, Onderdonk AB, Smith RS, Kasper DL. Structure-function relationships for polysaccharide-induced intra-abdominal abscesses. Infect Immun 1994;62:3590-3593.
42. Tzianabos AO, Onderdonk AB, Zaleznik DF, Smith RS, Kasper DL. Structural characteristics of polysaccharides that induce protection against intra-abdominal abscess formation. Infect Immun 1994;62:4881-4886.
43. Brubaker JO, Li Q, Tzianabos AO, Kasper DL, Finberg RW. Mitogenic activity of purified capsular polysaccharide A from Bacteroides fragilis: differential stimulatory effect on mouse and rat lymphocytes in vitro. J Immunol 1999;162:2235-2242.
44. Tzianabos AO, et al. T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria. J Biol Chem 2000;275:6733-6740.
45. Kalka-Moll WM, et al. Effect of molecular size on the ability of zwitterionic polysaccharides to stimulate cellular immunity. J Immunol 2000;164:719-724.
46. Wang Y, Kalka-Moll WM, Roehrl MH, Kasper DL. Structural basis of the abscess-modulating polysaccharide A2 from Bacteroides fragilis. Proc Natl Acad Sci USA 2000;97:13478-13483.
47. Kreisman LS, Friedman JH, Neaga A, Cobb BA. Structure and function relations with a T-cell-activating polysaccharide antigen using circular dichroism. Glycobiology 2007;17:46-55.
48. Avci FY, Kasper DL. How bacterial carbohydrates influence the adaptive immune system. Annu Rev Immunol 2010;28:107-130.
49. Klein Klouwenberg P, Bont L. Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines. Clin Dev Immunol 2008;2008:628963.
50. Poolman JT. Pneumococcal vaccine development. Expert Rev Vaccines 2004;3:597-604.
51. Kalka-Moll WM, Tzianabos AO, Bryant PW, Niemeyer M, Ploegh HL, Kasper DL. Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. J Immunol 2002;169:6149-6153.
52. Cobb BA, Wang Q, Tzianabos AO, Kasper DL. Polysaccharide processing and presentation by the MHCII pathway. Cell 2004;117:677-687.
53. Duan J, Avci FY, Kasper DL. Microbial carbohydrate depolymerization by antigen-presenting cells: deamination prior to presentation by the MHCII pathway. Proc Natl Acad Sci USA 2008;105:5183-5188.
54. Ryan SO, Bonomo JA, Zhao F, Cobb BA. MHCII glycosylation modulates Bacteroides fragilis carbohydrate antigen presentation. J Exp Med 2011;208:1041-1053.
55. Frayser M, Sato AK, Xu L, Stern LJ. Empty and peptide-loaded class II major histocompatibility complex proteins produced by expression in Escherichia coli and folding in vitro. Protein Expr Purif 1999;15:105-114.
56. Li Y, Li H, Martin R, Mariuzza RA. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins. J Mol Biol 2000;304:177-188.
57. Dustin ML, et al. Low affinity interaction of human or rat T cell adhesion molecule CD2 with its ligand aligns adhering membranes to achieve high physiological affinity. J Biol Chem 1997;272:30889-30898.
58. Trombetta ES, Helenius A. Lectins as chaperones in glycoprotein folding. Curr Opin Struct Biol 1998;8:587-592.
59. Wormald MR, Dwek RA. Glycoproteins: glycan presentation and protein-fold stability. Structure 1999;7:R155-R160.
60. Barrera C, Espejo R, Reyes VE. Differential glycosylation of MHC class II molecules on gastric epithelial cells: implications in local immune responses. Hum Immunol 2002;63:384-393.
61. Campbell BJ, Yu LG, Rhodes JM. Altered glycosylation in inflammatory bowel disease: a possible role in cancer development. Glycoconj J 2001;18:851-858.
62. Jennings HJ, Lugowski C, Young NM. Structure of the complex polysaccharide C-substance from Streptococcus pneumoniae type 1. Biochemistry (Mosc) 1980;19:4712-4719.
63. Lindberg B, Lindqvist B, Lonngren J, Powell DA. Structural studies of the capsular polysaccharide from Streptococcus pneumoniae type 1. Carbohydr Res 1980;78:111-117.
64. Tzianabos AO, Wang JY, Lee JC. Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides. Proc Natl Acad Sci USA 2001;98:9365-9370.
65. Young NM, Kreisman LS, Stupak J, Maclean LL, Cobb BA, Richards JC. Structural characterization and MHCII-dependent immunological properties of the zwitterionic O-chain antigen of Morganella morganii. Glycobiology 2011;21:1266-1276.
66. Baddiley J, Buchanan JG, Rajbhandary UL, Sanderson AR. Teichoic acid from the walls of Staphylococcus aureus H. Structure of the N-acetylglucosaminyl-ribitol residues. Biochem J 1962;82:439-448.
67. Sanderson AR, Strominger JL, Nathenson SG. Chemical structure of teichoic acid from Staphylococcus aureus, strain Copenhagen. J Biol Chem 1962;237:3603-3613.
68. Choi YH, Roehrl MH, Kasper DL, Wang JY. A unique structural pattern shared by T-cell-activating and abscess-regulating zwitterionic polysaccharides. Biochemistry (Mosc) 2002;41:15144-15151.
69. Velez CD, Lewis CJ, Kasper DL, Cobb BA. Type I Streptococcus pneumoniae carbohydrate utilizes a nitric oxide and MHC II-dependent pathway for antigen presentation. Immunology 2009;127:73-82.
70. Stephen TL, et al. Transport of Streptococcus pneumoniae capsular polysaccharide in MHC Class II tubules. PLoS Pathog 2007;3:e32.
71. Weidenmaier C, McLoughlin RM, Lee JC. The zwitterionic cell wall teichoic acid of Staphylococcus aureus provokes skin abscesses in mice by a novel CD4+ T-cell-dependent mechanism. PLoS ONE 2010;5:e13227.
72. Pragani R, Seeberger PH. Total synthesis of the Bacteroides fragilis zwitterionic polysaccharide A1 repeating unit. J Am Chem Soc 2011;133:102-107.
73. Wu X, Cui L, Lipinski T, Bundle DR. Synthesis of monomeric and dimeric repeating units of the zwitterionic type 1 capsular polysaccharide from Streptococcus pneumoniae. Chemistry 2010;16:3476-3488.
74. Gordon HA. Morphological and physiological characterization of germfree life. Ann N Y Acad Sci 1959;78:208-220.
75. Glimstedt G. Bakterienfreie Meerscheinchen. Acta Pathol Microbiol Scand 1936;30:1-295.
76. Guy-Grand D, Griscelli C, Vassalli P. The mouse gut T lymphocyte, a novel type of T cell. Nature, origin, and traffic in mice in normal and graft-versus-host conditions. J Exp Med 1978;148:1661-1677.
77. Sudo N, Sawamura S, Tanaka K, Aiba Y, Kubo C, Koga Y. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J Immunol 1997;159:1739-1745.
78. Rook GA, Brunet LR. Give us this day our daily germs. Biologist (London) 2002;49:145-149.
79. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005;122:107-118.
80. Gaboriau-Routhiau V, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 2009;31:677-689.
81. Ivanov II, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009;139:485-498.
82. Atarashi K, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011;331:337-341.
83. Sokol H, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105:16731-16736.
84. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007;449:804-810.
85. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229-241.
86. Yu Q, Tang C, Xun S, Yajima T, Takeda K, Yoshikai Y. MyD88-dependent signaling for IL-15 production plays an important role in maintenance of CD8 alpha alpha TCR alpha beta and TCR gamma delta intestinal intraepithelial lymphocytes. J Immunol 2006;176:6180-6185.
87. Atarashi K, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008;455:808-812.
88. Ivanov II, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008;4:337-349.
89. Huang JY, Lee SM, Mazmanian SK. The human commensal Bacteroides fragilis binds intestinal mucin. Anaerobe 2011;17:137-141.
90. Round JL, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011;332:974-977.
91. Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004;303:1662-1665.
92. Wang Q, et al. A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J Exp Med 2006;203:2853-2863.
93. Bell EB. Function of CD4 T cell subsets in vivo: expression of CD45R isoforms. Semin Immunol 1992;4:43-50.
94. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008;453:620-625.
95. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 2006;212:256-271.
96. Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F. CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 2003;197:111-119.
97. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-1290.
98. Mertens J, et al. Streptococcus pneumoniae serotype 1 capsular polysaccharide induces CD8CD28 regulatory T lymphocytes by TCR crosslinking. PLoS Pathog 2009;5:e1000596.
99. Menager-Marcq I, Pomie C, Romagnoli P, van Meerwijk JP. CD8+CD28- regulatory T lymphocytes prevent experimental inflammatory bowel disease in mice. Gastroenterology 2006;131:1775-1785.
100. Bilbo SD, Levkoff LH, Mahoney JH, Watkins LR, Rudy JW, Maier SF. Neonatal infection induces memory impairments following an immune challenge in adulthood. Behav Neurosci 2005;119:293-301.
101. Finegold SM, et al. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis 2002;35:S6-S16.
102. Heijtz RD, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA 2011;108:3047-3052.
103. Krause D, et al. The association of infectious agents and schizophrenia. World J Biol Psychiatry 2010;11:739-743.
104. Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2011;108(Suppl):4615-4622.
105. Kriegel MA, Sefik E, Hill JA, Wu HJ, Benoist C, Mathis D. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc Natl Acad Sci USA 2011;108:11548-11553.
106. Mix E, Meyer-Rienecker H, Hartung HP, Zettl UK. Animal models of multiple sclerosis--potentials and limitations. Prog Neurobiol 2010;92:386-404.
107. Ochoa-Reparaz J, et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol 2009;183:6041-6050.
108. Yokote H, Miyake S, Croxford JL, Oki S, Mizusawa H, Yamamura T. NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol 2008;173:1714-1723.
109. Ochoa-Reparaz J, et al. Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression. J Immunol 2010;185:4101-4108.
110. Ochoa-Reparaz J, et al. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol 2010;3:487-495.
111. Engelberg-Kulka H, Amitai S, Kolodkin-Gal I, Hazan R. Bacterial programmed cell death and multicellular behavior in bacteria. PLoS Genet 2006;2:e135.
112. Lewis K. Programmed death in bacteria. Microbiol Mol Biol Rev 2000;64:503-514.
113. Cohen-Poradosu R, McLoughlin RM, Lee JC, Kasper DL. Bacteroides fragilis-stimulated interleukin-10 contains expanding disease. J Infect Dis 2011;204:363-371.
114. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat Rev Drug Discov 2009;8:69-85.
115. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25years. J Nat Prod 2007;70:461-477.
116. Reeves CD. The enzymology of combinatorial biosynthesis. Crit Rev Biotechnol 2003;23:95-147.
117. Deshpande G, Rao S, Patole S, Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 2010;125:921-930.
118. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076-1079.
119. Kligler B, Hanaway P, Cohrssen A. Probiotics in children. Pediatr Clin North Am 2007;54:949-967; xi.
120. Thomas DW, Greer FR. Probiotics and prebiotics in pediatrics. Pediatrics 2010;126:1217-1231.
121. Stapleton AE, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis 2011;52:1212-1217.
122. Surawicz CM, Alexander J. Treatment of refractory and recurrent Clostridium difficile infection. Nat Revi Gastroenterol Hepatol 2011;8:330-339.
123. Husni RN, Gordon SM, Washington JA, Longworth DL. Lactobacillus bacteremia and endocarditis: review of 45 cases. Clin Infect Dis 1997;25:1048-1055.
124. Salminen MK, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004;38:62-69.
125. van der Waaij D, Berghuis-de Vries JM, Lekkerkerk L-V. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. J Hyg (Lond) 1971;69:405-411.
126. Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr 2001;73:399S-405S.
127. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008;6:e280.
128. Tannock GW, Miller JR, Savage DC. Host specificity of filamentous, segmented microorganisms adherent to the small bowel epithelium in mice and rats. Appl Environ Microbiol 1984;47:441-442.
129. De Filippo C, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 2010;107:14691-14696.
130. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009;1:6ra14.
131. Qin J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464:59-65.
132. Arumugam M, et al. Enterotypes of the human gut microbiome. Nature 2011;473:174-180.
133. Racke MK, Lovett-Racke AE. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective. J Immunol 2011;186:1887-1890.
134. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005;102:6449-6454.
135. Miller A, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998;92:113-121.
136. Aharoni R, Kayhan B, Brenner O, Domev H, Labunskay G, Arnon R. Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease. J Pharmacol Exp Ther 2006;318:68-78.
137. Aharoni R, Sonego H, Brenner O, Eilam R, Arnon R. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells. Immunol Lett 2007;112:110-119.
138. CDC. Ten great public health achievements--United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999;48:241-243.
139. CDC. Impact of vaccines universally recommended for children--United States, 1990-1998. MMWR Morb Mortal Wkly Rep 1999;48:243-248.
140. CDC. Ten great public health achievements --- worldwide, 2001-2010. MMWR Morb Mortal Wkly Rep 2011;60:814-818.
141. Pneumovax 23 [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., 2011.
142. Gallorini S, et al. Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides. Proc Natl Acad Sci USA 2009;106:17481-17486.
143. Abdulamir AS, Hafidh RR, Abubaker F. In vitro immunogenic and immunostimulatory effects of zwitterionized 23-valent pneumococcal polysaccharide vaccine compared with nonzwitterionized vaccine. Curr Ther Res Clin Exp 2010;71:60-77.
144. De Silva RA, Wang Q, Chidley T, Appulage DK, Andreana PR. Immunological response from an entirely carbohydrate antigen: design of synthetic vaccines based on Tn-PS A1 conjugates. J Am Chem Soc 2009;131:9622-9623.
145. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010;33:492-503.
146. McKinstry KK, Strutt TM, Swain SL. The potential of CD4 T-cell memory. Immunology 2010;130:1-9.
147. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010;33:530-541.
148. Zaiss DM, Boog CJ, van Eden W, Sijts AJ. Considerations in the design of vaccines that induce CD8 T cell mediated immunity. Vaccine 2010;28:7716-7722.
149. Lu YJ, Skovsted IC, Thompson CM, Anderson PW, Malley R. Mechanisms in the serotype-independent pneumococcal immunity induced in mice by intranasal vaccination with the cell wall polysaccharide. Microb Pathog 2009;47:177-182.
150. Malley R, et al. Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun 2006;74:2187-2195.
151. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731-2738.
152. Klaasen HL, Koopman JP, Poelma FG, Beynen AC. Intestinal, segmented, filamentous bacteria. FEMS Microbiol Rev 1992;8:165-180.
153. Bahrami B, Child MW, Macfarlane S, Macfarlane GT. Adherence and cytokine induction in Caco-2 cells by bacterial populations from a three-stage continuous-culture model of the large intestine. Appl Environ Microbiol 2011;77:2934-2942.
154. Child MW, Kennedy A, Walker AW, Bahrami B, Macfarlane S, Macfarlane GT. Studies on the effect of system retention time on bacterial populations colonizing a three-stage continuous culture model of the human large gut using FISH techniques. FEMS Microbiol Ecol 2006;55:299-310.
155. Klaasen HL, Koopman JP, Van den Brink ME, Bakker MH, Poelma FG, Beynen AC. Intestinal, segmented, filamentous bacteria in a wide range of vertebrate species. Lab Anim 1993;27:141-150.
156. Annunziato F, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204:1849-1861.
157. Kreisman LS, Cobb BA. Glycoantigens induce human peripheral Tr1 cell differentiation with gut-homing specialization. J Biol Chem 2011;286:8810-8818.
158. Lederberg J. Microbiology Past, Present, and Future. In: Joklik WK, Ljungdahl LG, O'Brien AD, von Graevenitz A, Yanofsky C eds. Microbiology: A Centenary Perspective. Washington, D.C.: ASM Press, 1999:xv-xx.
159. Eradication GCftCoS. The global eradication of smallpox. History of International Public Health, Number 4. Geneva: World Health Organization, 1980.
160. Larson HJ, Ghinai I. Lessons from polio eradication. Nature 2011;473:446-447.
161. Reingold A, et al. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005;54:893-897.
162. Thigpen MC, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011;364:2016-2025.
163. Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22-25, 2002. J Pediatr 2003;143:S163-S187.